SK Biopharm's operating profit for the third quarter of this year surpassed 100 billion won for the first time, leading to a more than 12% surge in its stock price. The significant improvement in both quarterly and cumulative performance has positively influenced investor sentiment.
According to the Korea Exchange, as of 2:44 PM on November 5, SK Biopharm shares were trading at 90,600 won, up 9,900 won (12.27%) from the previous trading day.
On the same day, SK Biopharm announced that its consolidated revenue for the third quarter reached 258.4 billion won, with an operating profit of 116.3 billion won. Compared to the same period last year, revenue increased by 34.8%, while operating profit rose by 65.9%.
Notably, this marks the first time the quarterly operating profit has exceeded 100 billion won, excluding any one-time gains. The substantial increase in both revenue and operating profit indicates a trend of improving profitability.
Cumulative performance also continued to show growth. By the end of the third quarter, cumulative revenue reached 723.7 billion won, a 43.2% increase compared to the same period last year. Cumulative operating profit stood at 303.1 billion won, reflecting a 92.3% rise during the same timeframe.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.